產品詳情
查看大圖

  • 產品名稱：CRL-2551 Panc 08.13 人胰腺癌細胞

  • 產品型號：CRL-2551
  • 產品廠商：其它品牌
  • 產品文檔：
你添加了1件商品 查看購物車
簡單介紹：
簡單介紹 CRL-2551 Panc 08.13 人胰腺癌細胞，原代細胞|細胞係|細胞株|菌種；細胞庫管理規範，提供的細胞株背景清楚，提供參考文獻和**培養條件！
詳情介紹：

CRL-2551 Panc 08.13 人胰腺癌細胞 的詳細介紹
CRL-2551 Panc 08.13 人胰腺癌細胞
ATCC® Number: CRL-2551™     Price:  
Designations: Panc 08.13
Depositors:  EM Jaffee
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: adherent
Organism: Homo sapiens (human)
Morphology: epithelial
Source: Organ: pancreas 
Disease: adenocarcinoma
Cellular Products: cytokeratins 7 and 18 [50655]
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
 
Tumorigenic: Yes
Oncogene: K-ras +
Antigen Expression: MHC class I +; MHC class II - [50655]
DNA Profile (STR): Amelogenin: X 
CSF1PO: 11 
D13S317: 13 
D16S539: 13 
D5S818: 13,14 
D7S820: 11 
THO1: 6,9.3 
TPOX: 8,12 
vWA: 18
Age: 85 years
Gender: male
Ethnicity: White
Comments: Panc 08.13 is a pancreatic adenocarcinoma epithelial cell line derived in 1995 from a primary tumor removed from the head-of-the-pancreas of a male with pancreatic adenocarcinoma. 
The cell line exhibits a K-ras oncogene mutation at codon 12 where a GGT --> GAT mutation resulted in substitution of aspartic acid for glycine. [50655] 
The cells have a reported plating efficiency of 40%. [50655]
Propagation: ATCC complete growth medium: RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate and supplemented with 10 Units/ml human insulin, 85%; fetal bovine serum, 15%
Temperature: 37.0°C
Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended 
Medium Renewal: Every 2 to 3 days 
Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach. 
Add fresh culture medium, aspirate and dispense into new culture flasks.
Preservation: culture medium 95%; DMSO, 5%
Doubling Time: 20 hrs
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 50655: Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602
 
ATCC® Number: CRL-2551™ Price: $417.00 
Designations: Panc 08.13 
Depositors: EM Jaffee 
Biosafety Level: 1 
Shipped: frozen 
Medium & Serum: See Propagation 
Growth Properties: adherent 
Organism: Homo sapiens (human) 
Morphology: epithelial


Source: Organ: pancreas 
Disease: adenocarcinoma 
Cellular Products: cytokeratins 7 and 18 [50655] 
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. 

Tumorigenic: Yes 
Oncogene: K-ras + 
Antigen Expression: MHC class I +; MHC class II - [50655] 
DNA Profile (STR): Amelogenin: X 
CSF1PO: 11 
D13S317: 13 
D16S539: 13 
D5S818: 13,14 
D7S820: 11 
THO1: 6,9.3 
TPOX: 8,12 
vWA: 18 
Age: 85 years 
Gender: male 
Ethnicity: White 
Comments: Panc 08.13 is a pancreatic adenocarcinoma epithelial cell line derived in 1995 from a primary tumor removed from the head-of-the-pancreas of a male with pancreatic adenocarcinoma. 
The cell line exhibits a K-ras oncogene mutation at codon 12 where a GGT --> GAT mutation resulted in substitution of aspartic acid for glycine. [50655] 
The cells have a reported plating efficiency of 40%. [50655] 
Propagation: ATCC complete growth medium: RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate and supplemented with 10 Units/ml human insulin, 85%; fetal bovine serum, 15%
Temperature: 37.0°C 
Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended 
Medium Renewal: Every 2 to 3 days 
Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach. 
Add fresh culture medium, aspirate and dispense into new culture flasks. 
Preservation: culture medium 95%; DMSO, 5% 
Doubling Time: 20 hrs 
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020 
References: 50655: Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602 
Related Links 
NCBI Entrez Search 
Make a Deposit 
Frequently Asked Questions 
Material Transfer Agreement 
Technical Support 
Related Cell Culture Products 

滬公網安備 31010902002433號